Assessment of HER2 status in extramammary Paget disease and its implication for disitamab vedotin, a novel humanized anti-HER2 antibody-drug conjugate therapy

{{article.zuoZheEn}}

PDF(949 KB)
PDF(949 KB)
Front. Med. ›› 2024, Vol. 18 ›› Issue (3) : 565-569. DOI: 10.1007/s11684-023-1046-2
LETTER TO FRONTIERS OF MEDICINE

Assessment of HER2 status in extramammary Paget disease and its implication for disitamab vedotin, a novel humanized anti-HER2 antibody-drug conjugate therapy

  • {{article.zuoZheEn}}
Author information +
History +

Highlights

{{article.highlightEn}}

Abstract

{{article.abstractEn}}

Author summary

{{article.authorSummayEn}}

Keywords

Cite this article

EndNote

Ris (Procite)

Bibtex

Download citation ▾
{{article.zuoZheEn_L}}. {{article.titleEn}}. Front. Med., 2024, 18(3): 565‒569 https://doi.org/10.1007/s11684-023-1046-2

References

Publishing order | Descend order by publishing year | Descend order by cited within

References

{{article.reference}}

RIGHTS & PERMISSIONS

{{article.copyright.year}} {{article.copyright.holder}}
PDF(949 KB)

Accesses

Citations

Detail
Sections
Recommended

/

〈 〉